✦ LIBER ✦

PND19 Pharmacological Costs of Recurrent-Remitent Multiple Sclerosis Treatment in Spain

✍ Scribed by Polanco, C.; Sanz-Granda, Á.; García-Jurado, L.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PND19 Cost Of The Relapse Of Multiple Sc

✍ L. Gubieras; V. Casado; L. Romero-Pinel; E. Matas; L. Bau; S. Martínez-Yélamos; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

PND14 Budgetary Impact of the Treatment

✍ García-Ruiz, A.J.; Izquierdo Ayuso, G.; Garcia-Agua Soler, N. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PND11 Budget Impact Analysis of First-Li

✍ R. Sánchez-de la Rosa; E. Sabater; M.A. Casado 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PND30 Cost Analysis of Glatiramer Acetat

✍ Sánchez-de la Rosa, R.; Sabater, E.; Casado, M.A. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

PND23 Cost of the Informal Care of Multi

✍ L. Gubieras; V. Casado; L. Romero-Pinel; E. Matas; L. Bau; S. Martínez-Yélamos; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

PND19 A LONG-TERM COST-EFFECTIVENESS MAR

✍ C Plesnila-Frank; N Putzki; D Eheberg; V Limmroth; Z Katsarava; SN Patel 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB